Option chain shows key data for Salarius Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Salarius Pharmaceuticals.

Salarius Pharmaceuticals (NASDAQ:SLRX) Stock, Option Chain

Salarius Pharmaceuticals

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Movers

News

Intraday Update

Markets

Trading Ideas

ASTS

ATPC

BALY

BLMZ

CERO

COOP

CTNT

EZFL

FORM

GSHD

HOTH

INDV

JBHT

KALU

KDLY

LULU

PEGA

PLXS

POAI

RBBN

SHYF

SLGL

SLNA

SLRX

STLA

TIVC

TWOU

VKTX

XCUR

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Wall Street US stocks

Earnings

Eurozone

Commodities

Dow Jumps 200 Points; Honeywell Trims Profit Outlook

xr:d:DAFp1nJl8vk:2,j:4184241900145690738,t:23072714

ADIL

AEVA

AROC

AZTR

CGBS

CLRB

CMAX

CMCSA

DRMA

EFSH

FEIM

FLYE

FTEL

ICLK

JAGX

KNSA

MEDP

MESO

MIRA

MLSS

MMYT

MSCI

NCPL

NUKK

NXPI

PCAR

PSIG

RNAZ

SMFL

SOAR

SPOT

STAF

TUSK

WBTN

ZION

Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals Inc

Warning: SLRX is at high risk of performing badly

Health Care

Press Releases

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting

Apollomics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Entero Therapeutics

Molecular Templates

NuCana

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Scorpius Holdings

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

HC Wainwright & Co.

Comments

Salarius Pharmaceuticals

Salarius Pharmaceuticals (SLRX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga